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Abstract
Diabetes mellitus (DM) is a metabolic syndrome that manifests a low grade 
of systemic inflammation that contributes to the development of cardiovascular 
diseases (CVDs). DM is a predominant risk factor for CVDs inducing structural 
changes in the heart, infiltration of fibrosis, apoptosis, and cardiac remodeling, 
all leading to myocardial infarction (MI), heart failure (HF), and sudden cardiac 
death. Furthermore, more than 80% of diabetic patients usually die from heart 
diseases or diabetic cardiomyopathy (DCM). Currently, HF is one of the main 
causes of mortality in the world despite advances in drug treatments. According to 
literature, a strong association exists between chronic inflammation and the devel-
opment of DCM. In order to have a better appreciation of the effect of diabetes and 
inflammation on the cardiovascular system (CVS), it is of paramount importance to 
have a better understanding of diabetes, the physiology of the CVS, and the patho-
physiology of DM. Thus, the present review highlights the role of chronic inflam-
mation in the complex interplay between the development of DM and DCM. Our 
understanding of the process is critical in the discovery of new targeted therapies 
for DCM and other forms of HF.
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1. Introduction
Cardiovascular diseases (CVDs) remain the leading cause of death in the world 
[1, 2]. By the year 2020, it is estimated that nearly 40% of all deaths worldwide 
will be due to CVDs, more than twice the percentage of deaths from cancer [3]. 
In line with the 2017 Update: A Report From the American Heart Association, 
CVDs account for one out of every three deaths or approximately 800,000 deaths 
in the United States, and coronary heart disease (CHD) accounts for most deaths 
due to CVDs, followed by stroke (1 of 20 deaths in the United States) and heart 
failure (HF) [4]. CVDs are considered multifactorial conditions which affect the 
essential components of the circulatory system of the human body including the 
heart, blood vessels and blood [5]. CVDs can either be congenital or acquired 
throughout people’s lifespan [6]. The rising incidence of such cardiovascular risk 
factors as unhealthy life styles (especially eating and physical inactivity), obesity, 
diabetes and hypertension can underlie an increase in CVDs especially coronary 
artery disease (CAD). The burden of chronic diseases, including CVDs, obesity, 
diabetes and cancers, is rapidly increasing worldwide. These non-communicable 
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diseases have become a major health concern and burden to mankind, not just in 
developed countries but also in developing countries [7]. Chronic inflammation 
and oxidative stress are associated with the development of various CVDs including 
hypertension, arrhythmias, CAD and HF. Globally, CVDs remain a leading cause of 
death despite the development of new drugs and novel treatments [2]. Recent data 
showed that the prevalence of macro-vascular complications including coronary 
artery disease (CAD), peripheral artery disease (PAD) and stroke is two to four 
times more common in people with diabetes than healthy subjects [8]. According 
to the Framingham Study, the frequency of CAD is twice as common in diabetic 
patients of both sexes [1]. Existing data highlight the complex nature of the cardio-
vascular system, and different signalling pathways may play various roles depend-
ing on the stages of the pathology. In order to have a better appreciation of the effect 
of CVDs on the increased morbidity and mortality rate, it is helpful to have a brief 
understanding of the physiology and pathophysiology of the cardiovascular system.
2. Cardiovascular system physiology and pathophysiology
The cardiovascular system (CVS) is composed of the blood, heart and blood 
vessels. The heart is a relentless muscular organ, which never stops pumping blood 
during life. It beats approximately 100,000 times per day, and each beat requires a 
vast amount of energy. The weight of the human heart is around 250–300 g for adult 
and a size similar to a closed fist. The heart rests on the diaphragm, near the midline 
of the thoracic cavity, and is surrounded by a fibrous sac called the pericardium [9]. 
The heart is divided into left and right sides by a septal wall. Each side of the heart is 
made up of two chambers, the atria and ventricles which are separated by atrioven-
tricular valves [9]. The left side of the heart delivers oxygen-rich blood to the body 
passing through the aortic valve to the aorta (systemic circulation), while the right 
side pumps blood to the lungs passing though the pulmonary valve and the pulmo-
nary artery for oxygen replenishment in the lungs (pulmonary circulation). The four 
valves of the heart ensure unidirectional flow of blood through the heart. The valves 
are opened and closed due to pressure differences between the heart chambers. The 
right atrium receives deoxygenated blood from the body through the superior and 
inferior vena cavae, while the left atrium receives oxygenated blood from the lungs 
through pulmonary veins. Coronary arteries supply the myocardium with oxygen-
rich blood (the left anterior descending coronary artery, the left circumflex artery 
and the right coronary artery). The apex of the heart is the pointed end, and the area 
opposite the apex is called the base of the heart [10]. HF develops when the volume 
of blood pumped from the heart is inadequate to meet the metabolic demands or 
needs of the body [11]. The traditional hemodynamic hypothesis is that diseases, 
which normally increase the hemodynamic burden of the heart, ultimately lead to 
HF by inducing defects in the contractility of cardiac myocytes. The hypothesis of 
depressed cardiac myocyte contractility in HF is in support of several other related 
studies [12, 13], but not all [14]. Previous investigations suggested that cardiac 
myocytes in the failing human heart undergo many alterations which result in a 
significant loss of contractile function. These alterations involved a reduction in 
α-myosin heavy chain gene expression along with a rise in β-myosin heavy chain 
gene expression, significant loss of myofilaments in myocytes and changes in 
cytoskeletal proteins [15].
There is general agreement about the contractile properties of the myocar-
dium, which can be similar in both normal and in failing heart muscle under basal 
conditions. However, the rate-related contractile reserve is absent or significantly 
reduced in failing human myocardium [16]. Many studies reported that during the 
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end-stage of HF, basal contractility is well preserved, but the ability to increase 
contractility with heart rate or sympathetic stimulation is severely depressed [17]. 
Thus, the fundamental changes in muscle performance and regulation can be 
explained by the poor pumping function, reduced exercise capacity and tachycar-
dia intolerance of the human failing heart [14]. HF can no longer be considered a 
simple contractile disorder or a disease of the heart alone [18]. Clinical manifesta-
tions are, in fact, the result of changes to the cellular, sub-cellular and molecular 
components of the heart and to mediators that drive homeostatic control mecha-
nisms. Cardiac remodelling (CR) is now generally accepted as a determinant of the 
clinical course of HF. CR is defined as genome expression, resulting in molecular, 
cellular and interstitial changes, and manifested clinically as changes in size, shape 
and function of the heart. CR is determined by the general process of adaptation, 
which allows for both the myocyte and the collagen network to adapt to new work-
ing conditions [19].
3. Inflammation
Inflammation is one of the body’s defence mechanisms, and there are commonly 
two types of inflammation, namely, acute and chronic inflammation. Acute inflam-
mation starts rapidly and becomes more severe in a short time, and the symptoms 
may last for a few days. On the other hand, chronic inflammation which is a long-
term inflammation in nature can last for prolonged periods of several months to 
years. Generally, the extent and effects of chronic inflammation vary with the cause 
of the injury and the ability of the body to repair and overcome the damage [4]. 
This review now describes the relevant data about inflammation induced by several 
risk factors leading to the onset of CVDs. Basically, an inflammatory response 
aims to reduce the agent that causes tissue injury and to induce appropriate wound 
healing and to restore tissue homeostasis [20]. A cascade of inflammatory pathways 
and mechanistic effects are supposedly well-orchestrated by the immune system 
in order to eradicate the causative agent. Several immune cells can change their 
number, morphology and nature depending on the stage and type of inflammation 
[20], provided that the immune response succeeds in repairing the initial tissue 
injury. However, in cases where the inflammation fails to resolve, the tissue injury, 
due to the persistence of the triggering agent(s) or due to unsuccessful repair of the 
initial tissue injury or dysfunction, a sustained underlying inflammatory process 
can develop, leading to further tissue dysfunction and detrimental consequences 
[21]. Several traditional and emerging risk factors are thought to influence the 
cardiovascular system especially inflammation-related chronic diseases, by their 
interrelation with underlying molecular and cellular manifestations. In turn, 
these can result in chronic inflammatory responses leading to the loss of tissue 
properties and subsequently dysfunction [22]. Apart from dyslipidaemia, other 
well-established risk factors are involved in the process including hypertension, 
diabetes and obesity. Inflammation that causes endothelial dysfunction seems to 
be the key causative underlying mechanistic player, at the molecular and cellular 
levels, for the onset and development of subsequent inflammation-related chronic 
disorders such as atherosclerosis and subsequent CVDs and renal disorders [23, 24]. 
Hypertension, diabetes and obesity have harmful effects of oxidised low-density 
lipoprotein cholesterol, initiating a chronic inflammatory reaction, the result of 
which is a vulnerable plaque, prone to rupture and thrombosis. Epidemiological and 
clinical studies have shown strong and consistent relationships between markers of 
inflammation and risk of future cardiovascular events [3]. Inflammation is widely 
considered to be an important contributing factor in atherogenesis and the risk 
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of athero-thrombotic complications. Baseline measurements of some inflamma-
tory markers are well-known to be predictive risk factors for future CVD events 
in prospective epidemiological studies. Inflammatory markers dominant in the 
literature are acute phase response (APR)-associated, and they include fibrinogen 
and C-reactive protein (CRP) [25].
The presence of subclinical inflammation is accompanied by an elevated 
concentration of high-sensitivity CRP and increased concentrations of other 
inflammatory markers. Epidemiological studies suggest strong association between 
high-sensitivity CRP concentrations and CVD risks [37].
4. Risk factors for cardiovascular diseases
There are a number causal risk factors which are associated with CVDs and it is 
of paramount importance to understand and recognise these risk factors in order to 
predict and more so, to prevent CVDs. Risk factors may be causal or just a marker 
of risk(s) in nature and they are often called “innocent bystanders” [26]. The WHO 
has identified high blood pressure, tobacco use, physical inactivity, unhealthy diet, 
overweight, obesity, diabetes, high blood glucose and high cholesterol, as the main 
causal factors of the global burden of CVDs [27]. This review will now focus on 
how hypertension and diabetes mellitus can lead to heart failure (HF) and diabetes-
induced cardiomyopathy (DCM).
5. Hypertension and ischaemic heart disease
Hypertension is a well-recognised risk factor for CVDs [28]. In fact, 14 weeks 
of hypertension can increase left ventricular weight by 30% and wall thickness by 
42%, while the number of myocytes and total length of capillaries remain constant. 
Hypertrophy of myocytes is associated with reduced mitochondria to myofibril 
ratio [29]. Thus, physiological and pathological cardiac hypertrophies are caused 
by different stimuli and functionally distinguishable. A pathological stimulus 
causing pressure overload like hypertension produces an increase in systolic wall 
stress which results in in concentric hypertrophy (a heart with a very thick wall but 
with relatively small cavities) [30]. In the pathological hypertrophied heart, the 
function may decompensate, resulting in left ventricle dilation and HF. However, in 
physiological hypertrophy, the function does not decompensate [30]. Accordingly, 
regular exercise training (ET) can induce beneficial effects in the myocardium. 
Cardiac action potential duration (CAPD) of the hypertrophied heart is prolonged 
compared to control [31]. According to literature, mortality rates from coronary 
artery and cerebrovascular diseases can increase progressively as blood pressure 
increases [21]. CAD is caused by the accumulation of lipid and inflammatory cells 
in the arterial walls to form atherosclerotic plaques. Unstable coronary plaques are 
prone to erosion or rupture, obstructing coronary blood flow and causing an acute 
myocardial infraction (MI). It is now known that various CVDs can alter the ultra-
structure of the heart. Myocardial ischaemia develops when the coronary blood 
supply to the myocardium is reduced either in terms of absolute flow rate (low-flow 
or no flow) or relative to increased tissue demand. The main feature of ischaemia 
is that oxygen supply to the mitochondria is insufficient to support oxidative 
phosphorylation [32]. After the onset of ischaemia, ultrastructural changes in the 
myocardium occur rapidly. These changes can be considered as reversible altera-
tions if reperfusion of the tissue can be effected quickly. However, when ischaemia 
lasts for more than 20–30 min without collateral flow, the result is a transition from 
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a state of reversible ultrastructural alterations to a state of irreversible tissue injury 
[33]. An early consequence of myocardial ischaemia is depression of myocardial 
contractility. Also during ischaemia, arrhythmias may occur, ranging in severity 
from isolated ventricular premature beats, through runs of ventricular tachycardia, 
to ventricular fibrillation [34]. During ischaemia, there is a reduced availability of 
oxygen and the metabolic substrates, leading to a deficit of high-energy phosphates. 
In addition, the Ca2+ uptake mechanisms in the sarcoplasmic reticulum (SR) of 
cardiac myocytes are impaired, leading to intracellular free Ca2+ accumulation or 
elevated diastolic [Ca2+]i [35].
6. Diabetes induced cardiomyopathy (DCM)
CVDs are closely associated with diabetes-induced hyperglycaemia, resulting 
in the death in 80% of people with diabetes [1]. Diabetic cardiomyopathy (DCM) 
is defined as a disorder of the heart muscle caused by diabetes. It results in patho-
logical cardiac remodelling without previous incidence of CAD, hypertension and 
valvular disease. The exact cellular, subcellular and molecular mechanisms of DCM 
are complex and remain unclear [2]. Thus, further studies are essential for better 
understanding of the mechanism(s) of DCM and also in reversing the pathologi-
cal cardiac remodelling induced by diabetes [3]. The increased frequency of HF in 
diabetic patients can persist despite correction for age, obesity, hypercholesterol-
emia and CAD. DCM is characterized by diastolic dysfunction, which can lead to 
the development of systolic dysfunction [36]. Echocardiography for patients with 
type 1 diabetes mellitus (T1DM) without known CAD shows diastolic dysfunction 
with a reduction in early diastolic filling, increase in atrial filling, an extension of 
iso-volumetric relation and increased numbers of supra-ventricular premature 
beats. The most common abnormality observed in asymptomatic diabetics is left 
ventricular (LV) diastolic dysfunction, likely resulting from greater LV myocardial 
and vascular stiffness [37]. A deep understanding of its development is necessary 
for the early diagnosis and subsequent treatment of diabetes-related cardiovascular 
diseases.
There is a rapidly growing literature on DCM investigating the structural, func-
tional and metabolic changes that occur in the diabetic myocardium and how these 
changes contribute to the development of DCM in humans [38, 39]. The structural 
changes include left ventricular hypertrophy, interstitial fibrosis, increased cell 
death and oxidative stress and myocardial lipotoxicity [40, 41]. The functional 
changes include diastolic dysfunction, systolic dysfunction and impaired contractile 
reserve. Metabolic changes include altered substrate utilisation and mitochondrial 
dysfunction [42]. In type 2 diabetes mellitus (T2DM), left ventricular mass is an 
independent marker of cardiovascular risks that often occur independently of 
atrial blood pressure. Hence, diabetes is an independent risk factor leading to left 
ventricular hypertrophy, myocardial stiffness and inflammation [43]. DCM is also 
characterized by interstitial fibrosis, mostly composed of collagen and perivascular 
fibrosis [44]. In biopsies from diabetic heart patients, the deposition of collagen 
around the vessel and between myofibres is significantly raised. Furthermore, 
lipofuscin (which is a brown pigment composed of lipid-containing residues), 
cholesterol and myocardial triglyceride is also significantly increased in cardiac 
tissue biopsies from the left ventricle [45].
During DCM, hyperglycaemia (HG) can lead to both acute reversible cellular 
metabolism damage and irreversible changes in endogenous macromolecules in 
the heart [46]. Elevated blood HG can affect many organs in the body including 
the kidneys, the eyes, the nerves and the heart resulting in long-term damage and 
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failure [47, 48]. The first target of HG-induced damage is the microvasculature. 
As a result, the small blood vessels will initiate a systematic complication [49, 
50]. Increased oxidative stress (OS) is a key contributor to HG-induced diabetic 
damages [51]. Increased OS is a possible biochemical mechanism linking the onset 
of DM and its complications due to OS [52–54]. Furthermore, hypertrophy and 
myocardial fibrosis are also associated with endothelial cell dysfunction (ECD), 
inflammation and abnormal vascular remodelling seen in DCM [45]. The activa-
tion of endothelial cells (ECs) from a quiescent phenotype to vasoconstriction, 
pro-inflammatory and pro-apoptotic state can also result in ECD [55]. The expo-
sure of the blood vessels to high fluctuating levels of elevated blood glucose (HG) 
is a known factor for ECD [56].
An increase in myocardial stiffness is an early sign in the pathogenesis of 
DCM. This increase in myocardial tissue stiffness is a result of increased collagen 
production by fibroblasts along with the fibrotic replacement of apoptotic/necrotic 
cells [57]. Collagen type I and type III fibres accumulate in the epicardial (EPI) 
layer of the heart and perivascular domains, whereas type IV is mostly found in 
the endocardial (ENDO) layer of the myocardium [58]. The increased stiffness in 
diabetic hearts may be due to an increase in the stiffness of cardiac myocytes within 
the myocardium. Although the changes in stiffness are not dramatic, they may be 
enough to cause or to contribute to increased cardiac workload over time, leading 
to DCM progression [59]. At the molecular level, DCM leads to prolongation and 
enhanced temporal dispersion of the repolarization phase of cardiac action poten-
tial (CAP) in myocytes leading to alterations of the spatial heterogeneity of ion 
channel expression and AP duration [60]. The major recognised factors of DCM are 
insulin resistance (IR) and hyperinsulinemia [61]. A disruption of insulin-mediated 
glucose metabolism occurs during IR and hyperinsulinemia which can significantly 
alter the efficiency of metabolism in cardiac muscle as well as skeletal muscle. The 
diabetic heart is affected by insulin in both systematic metabolism abnormalities 
via direct effects on insulin signalling pathways in the myocardium [62]. The early 
recognised change in insulin resistance in the heart is the impaired ability of insulin 
to increase glucose transport [63]. Recently, it was found that IR is linked to cardiac 
contractile dysfunction. In addition, a previous study, has developed a new IR rat 
model in which the animals were fed on a high cholesterol fructose (HCF) diet 
[63]. These results demonstrate that IR is directly linked to biochemical changes 
in the heart, thereby contributing to the development of DCM. Despite the recent 
advances in this field, our understanding of the initiation and progress of DCM is 
still very limited.
7. Conclusion
CVDs are considered as the leading cause of deaths globally and they are mul-
tifactorial in nature affecting the heart, the blood vessels and the blood. The flow 
diagram in Figure 1 reveals the processes and mechanism(s) whereby diabetes-
induced elevated hyperglycemia, hyperinsulinemia and hyperlipidemia can lead to 
oxidative stress, inflammation, mitochondrial dysfunction and other mechanisms, 
all resulting in cardiac dysfunction, including HF, DCM ,arrhythmias and sudden 
cardiac death., Initially, these dysfunctions are induced at the cellular, sub-cellular 
and molecular levels in the heart and they include changes in size, shape and 
function of the myocardium, including cellular calcium homeostasis. If the heart is 
left untreated, then it can develop, hypertrophy and disarray of the myofilaments 
and subsequently apoptosis and infiltration of fibrosis leading to remodeling of the 
myocardium. Moreover, chronic inflammation associated with cardiac dysfunction 
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can also result in damage and subsequent failure to a number of organs in the body 
including the heart and kidneys where the dynamics of blood flow is disturbed. In 
relation to the myocardium, there is an increase in CAPD and subsequently elevated 
diastolic [Ca2+]. The end-result is a delay in contraction and blood ejection from 
the heart. This leads to slower relaxation and filling process in the heart. Over time, 
the whole process will lead to a weak heart or DCM and subsequently, death of the 
patient. The cellular and molecular mechanisms associated with chronic inflamma-
tion and the cardiovascular system are not fully known and the literature suggests 
the need for further research into novel inflammatory markers of CVD risk.
Figure 1. 
Changes occurring in the heart during diabetic cardiomyopathy. DCM in turn can lead to structural and 
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